Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Trial Profile

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs PF 06760805 (Primary)
  • Indications Streptococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Aug 2018 Status changed from recruiting to completed.
    • 13 Feb 2018 Planned End Date changed from 13 Jun 2018 to 5 Jun 2018.
    • 13 Feb 2018 Planned primary completion date changed from 13 Jun 2018 to 5 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top